|
|
|
Brian Kingwell is a member of the firms' Executive Committee. For over 20 years, his practice has focused on patent prosecution and strategic patent portfolio counseling in the areas of molecular biology, biochemistry, chemistry, chemical engineering and medical devices. He has wide-ranging experience in obtaining patents for products such as a novel family of heterocyclic antibiotics, The InsectSelect™ protein expression vector, high oleic acid brassica juncea plants, in situ combustion processes for recovery of hydrocarbons, heavy metal waste remediation processes and Glybera®, the first human gene therapeutic approved in Europe. Mr. Kingwell is also the inventor of a patented medical device that has been marketed internationally, the PeriPatch™ Sleeve.
Rankings and recognition
- Named Best Lawyers' 2012 Vancouver Biotechnology Law Lawyer of the Year
- Listed in The Best Lawyers in Canada under Intellectual Property Law and Biotechnology Law
- Recognized in The Canadian Legal LEXPERT® Directory under Intellectual Property and Biotechnology
- Selected to appear in IAM Patent 1000 – The World's Leading Patent Practitioners 2012
- Martindale-Hubbell, Peer Review Rated, AV® Preeminent™
|
|
|
Memberships
- Fellow, Intellectual Property Institute of Canada; Chair of the Biotechnology Legislation Committee
- Member and past President, Patent and Trade-mark Association of British Columbia
- Member, Genome British Columbia's Genomics, Society, and Ethics Advisory Committee
- Member, Canadian Bar Association
Speaking engagements
- Moderated IPIC's "Academic Research, Experimental Use and Patent Infringement" webinar, December 6, 2012
- "The role of patents in drug research" (co-presenters: Andris D. Macins, Jeffrey D. Morton and J. Christopher Robinson), Centre for Drug Research and Development, Vancouver, March 2010
Teaching activities
- "Patent Law," University of British Columbia, Vancouver 2002
- "Patent Law," University of Victoria, Victoria, BC 2001-2005
Publications
- "Bottlenecks in translating genomics from the academy into the real world: risk, trust and communication" (co-authors: R. E. Ommer, J. Atkinson-Grosjean, C. Benoit, N. R. Caron, R. Downey, J. K. Hall, J. E. Halliwell and G. C. van Kooten), position paper prepared for Genome British Columbia, January 29th, 2012
- "A 'Bright Line' for the Patentability of Stem Cells?" (co-authors: Jeffrey D. Morton and Michael D. Manson), Intellectual Property Magazine, 2010
- "Intellectual Property Protection for Transgenic Plants" (co-author: Joy D. Morrow) in "Transgenic Plants and Crops," edited by G. Khachatourians, Alan McHughen, Ralph Scorza, Wai-Kit Nip and Y. H. Hui, Marcel Dekker, 2002
- "Recent Developments in Biotechnology Law" (co-author: J. Christopher Robinson), Lexpert, 2001
- "Functional Language and Fingerprints," Canadian Intellectual Property Review (1993), vol. 10, No. 1, pp. 87
- "Identification and characterization of a protein associated with the stembody using autoimmune sera from patients with systemic sclerosis" (co-authors: M.J. Fritzler, J. Decoteau and J.B. Rattner), Cell Motility and the Cytoskeleton (1987), 8(4), pp. 360-7
- "Mammalian kinetochore/centromere composition: a 50 kDa antigen is present in the mammalian kinetochore/centromere" (co-author: J.B. Rattner), Chromosoma (1987), 95(6), pp. 403-7
|
|
